AGP Picks
View all

Sci-Tech North Carolina: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Sci-Tech North Carolina.

Press releases published on November 18, 2026

ESET continues global expansion, opens U.S. office in Boston
Battle Motors Awards Core Molding Technologies Development of Large-Scale Composite Solutions for Refuse Trucks
Iambic Presents Preclinical Data for CDK2/4 Inhibitor IAM-C1 and Brain-Penetrant KIF18A Inhibitor IAM217 at 2026 EORTC-NCI-AACR Symposium
Rantizo (Nasdaq: RNTZ) Issues Letter to Shareholders Outlining Revenue-Focused American Drone Strategy After $258.8 Million Acquisition
ROC Ranked Number 326 Fastest-Growing Company in North America on the 2026 Deloitte Technology Fast 500™
Enlivex Announces Positive Interim DSMB Safety Review, Supporting Continued Enrollment in Phase IIb Knee Osteoarthritis Trial
Genetec introduces Security Center MCP connector to accelerate physical security operations in large-scale deployments
Genetec lance le connecteur MCP de Security Center pour accélérer les opérations de sécurité physique dans les déploiements à grande échelle
AlphaSense Ranked a Fastest-Growing Company in North America on the 2026 Deloitte Technology Fast 500™
3 E Network Technology Group Limited Regains Compliance with Nasdaq Listing Requirements
TTEC Identifies Six CX Trends Businesses Must Prepare for in 2027
Immuneering Presents Additional Data Demonstrating Atebimetinib’s Broad Potential as a Backbone for Combination Therapy in Pancreatic Cancer
Immuneering Presents Data That Supports Expanding the Clinical Evaluation of Atebimetinib to Anaplastic Thyroid Cancer
SELLAS Life Sciences meldet positive Ergebnisse der zulassungsrelevanten Phase III-Studie REGAL zu immuntherapeutischem Krebsimpfstoff Galinpepimut-S (GPS), die eine statistisch signifikante und klinisch bedeutsame Verbesserung in Bezug auf…
SELLAS Life Sciences annonce une les résultats positifs de l’étude pivot de phase III REGAL : l’utilisation du vaccin immunothérapeutique contre le cancer, le Galinpepimut-S (GPS), a démontré une amélioration statistiquement significative et…
חברת SELLAS Life Sciences מודיעה על נתונים חיוביים מניסוי ה-REGAL – מחקר מכריע בשלב 3 – המראים כי החיסון האימונותרפי לסרטן, Galinpepimut-S (GPS), הוביל לשיפור מובהק סטטיסטית ומשמעותי מבחינה קלינית בהישרדות הכוללת בקרב חולים עם לוקמיה מיאלואידית חריפה (…
SELLAS Life Sciences Mengumumkan Data Positif dari Uji Klinis Penting Fase 3 REGAL yang Menunjukkan bahwa Vaksin Imunoterapi Kanker Galinpepimut-S (GPS) Memberikan Peningkatan Kesintasan Keseluruhan yang Signifikan Secara Statistik dan Bermakna Secara…
セラス・ライフ・サイエンシズ、リーガルと呼ばれる重要な第3相試験の良好なデータを発表、がん免疫療法ワクチンであるガリンペピムト-S (GPS)…
SELLAS 라이프사이언스, 면역항암 백신 갈린페피무트-S(GPS)의 급성 골수성 백혈병 환자 대상 전체생존기간 개선 효과 입증한 핵심 임상 3상 REGAL 시험에서 긍정적 결과 발표
SELLAS Life Sciences Mengumumkan Data Positif Kajian Pivotal Fasa 3 REGAL yang Menunjukkan bahawa Vaksin Kanser Imunoterapeutik Galinpepimut-S (GPS) Meningkatkan Kelangsungan Hidup Keseluruhan secara Signifikan dari Segi Statistik dan Bermakna dari…

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Sci-Tech North Carolina

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.